John F. Rothman is VP Clinical Development at Advaxis, Inc. (ADXS). They have made 2 open-market trades across 1 company since 2007, most recently 2007-10-25.
CIK 0001238323
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $33K since 2007, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADXS | 275,775 | $66K |
Shares reported on the most recent Form 4, priced at the 2007-10-30 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.